- Home
- XBP vs SABS Comparison
XBP vs SABS Comparison
Compare XBP & SABS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- XBP
- SABS
- Stock Information
- Founded
- XBP N/A
- SABS 2014
- Country
- XBP United Kingdom
- SABS United States
- Employees
- XBP N/A
- SABS N/A
- Industry
- XBP Business Services
- SABS Biotechnology: Pharmaceutical Preparations
- Sector
- XBP Consumer Discretionary
- SABS Health Care
- Exchange
- XBP Nasdaq
- SABS Nasdaq
- Market Cap
- XBP 32.3M
- SABS 32.1M
- IPO Year
- XBP N/A
- SABS N/A
- Fundamental
- Price
- XBP $1.10
- SABS $3.53
- Analyst Decision
- XBP
- SABS Strong Buy
- Analyst Count
- XBP 0
- SABS 5
- Target Price
- XBP N/A
- SABS $12.40
- AVG Volume (30 Days)
- XBP 210.4K
- SABS 69.6K
- Earning Date
- XBP 11-12-2024
- SABS 11-06-2024
- Dividend Yield
- XBP N/A
- SABS N/A
- EPS Growth
- XBP N/A
- SABS N/A
- EPS
- XBP N/A
- SABS N/A
- Revenue
- XBP $157,146,000.00
- SABS $1,512,723.00
- Revenue This Year
- XBP N/A
- SABS N/A
- Revenue Next Year
- XBP N/A
- SABS N/A
- P/E Ratio
- XBP N/A
- SABS N/A
- Revenue Growth
- XBP N/A
- SABS N/A
- 52 Week Low
- XBP $0.79
- SABS $2.16
- 52 Week High
- XBP $4.33
- SABS $6.30
- Technical
- Relative Strength Index (RSI)
- XBP 50.04
- SABS 46.39
- Support Level
- XBP $0.96
- SABS $3.50
- Resistance Level
- XBP $1.33
- SABS $4.35
- Average True Range (ATR)
- XBP 0.13
- SABS 0.41
- MACD
- XBP 0.01
- SABS -0.07
- Stochastic Oscillator
- XBP 37.16
- SABS 19.22
About XBP XBP Europe Holdings Inc.
XBP Europe Holdings Inc is a pan-European integrator of bills, payments, and related solutions and services seeking to enable digital transformation. It provides business process management solutions with proprietary software suites and deep domain expertise, serving as a technology and operations partner for its clients' strategic journeys and streamlining their complex, disconnected payment processes. It has two segments Bills and Payments focusing on optimizing how bills and payments are processed by businesses of all sizes and industries and Technology focuses on sales of recurring and perpetual software licenses and related maintenance, hardware solutions, and related maintenance and professional services. It generates the majority of its revenue from the Bills and Payments segment.
About SABS SAB Biotherapeutics Inc.
SAB Biotherapeutics Inc is a clinical stage biopharmaceutical company focused on the development and commercialization of a portfolio of products from its proprietary immunotherapy platform to produce fully targeted human polyclonal antibodies, without using human plasma or serum. The company's novel DiversitAb platform enables the rapid production of large amounts of targeted human polyclonal antibodies, leveraging transchromosomic cattle (Tc Bovine) that have been genetically designed to produce human antibodies (immunoglobulin G) rather than bovine in response to an antigen. Animal antibodies have been made in rabbits, sheep and horses.